

Active Biotech Q3 2023 - Rights Issue Paves the Way for Phase II in Myelofibrosis

Redeye comments on Active Biotech's Q3 report and the rights issue that was simultaneously announced.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Active Biotech Q3 2023 - Rights Issue Paves the Way for Phase II in Myelofibrosis](#)